Advances in genetics, biotechnology, immunology and statistics have led to better understanding of the pathogenesis of rheumatoid arthritis and new treatments directed at a variety of molecular targets. Many investigators believe that the next great advances in the treatment of rheumatoid arthritis will include additional new drug therapies, as well as more efficient, cost effective, and successful treatment outcomes in individual patients. This session will present current approaches to identify genetic, serum, and gene expression markers to predict treatment responses to various drugs, with an emphasis on rheumatoid arthritis.
Upon completion of this session, participants should be able to:
- describe the major experimental approaches to identifying predictors of treatment responses in rheumatoid arthritis
- identify the obstacles to personalized medicine in rheumatoid arthritis and other complex diseases
- explain what information may be learned by analysis of potential biomarkers and pathogenic pathways in rheumatoid arthritis
|Moderator:||Bruce N. Cronstein, MD, New York Univ Medical Center|
To see other sessions for this day, use the date buttons to the left.